The Central Drugs Standard Control Organisation has instructed Tamil Nadu-based Global Pharma Healthcare to stop manufacturing all the products under the category of ophthalmic preparation till the completion of an investigation. The move came soon after the U.S. Centers for Disease Control and Prevention linked the company’s eye drops to 55 adverse events in the U.S. On Friday, a joint …
